Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach
- PMID: 24303025
- PMCID: PMC3841158
- DOI: 10.1371/journal.pone.0080751
Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach
Abstract
Psoriasis is a multifactorial inflammatory skin disease characterized by increased proliferation of keratinocytes, activation of immune cells and susceptibility to metabolic syndrome. Systems biology approach makes it possible to reveal novel important factors in the pathogenesis of the disease. Protein-protein, protein-DNA, merged (containing both protein-protein and protein-DNA interactions) and chemical-protein interaction networks were constructed consisting of differentially expressed genes (DEG) between lesional and non-lesional skin samples of psoriatic patients and/or the encoded proteins. DEGs were determined by microarray meta-analysis using MetaOMICS package. We used STRING for protein-protein, CisRED for protein-DNA and STITCH for chemical-protein interaction network construction. General network-, cluster- and motif-analysis were carried out in each network. Many DEG-coded proteins (CCNA2, FYN, PIK3R1, CTGF, F3) and transcription factors (AR, TFDP1, MEF2A, MECOM) were identified as central nodes, suggesting their potential role in psoriasis pathogenesis. CCNA2, TFDP1 and MECOM might play role in the hyperproliferation of keratinocytes, whereas FYN may be involved in the disturbed immunity in psoriasis. AR can be an important link between inflammation and insulin resistance, while MEF2A has role in insulin signaling. A controller sub-network was constructed from interlinked positive feedback loops that with the capability to maintain psoriatic lesional phenotype. Analysis of chemical-protein interaction networks detected 34 drugs with previously confirmed disease-modifying effects, 23 drugs with some experimental evidences, and 21 drugs with case reports suggesting their positive or negative effects. In addition, 99 unpublished drug candidates were also found, that might serve future treatments for psoriasis.
Conflict of interest statement
Figures
References
-
- Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133: 377–385. - PubMed
-
- Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370: 263–271. - PubMed
-
- Farkas A, Kemeny L (2012) Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle. Int Immunopharmacol 13: 215–218. - PubMed
-
- Armstrong AW, Harskamp CT, Armstrong EJ (2013) Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
